An invention may turn one of the most widely used materials for biomedical applications into wearable devices to help monitor heart health.
A team from Purdue University developed self-powered wearable triboelectric nanogenerators (TENGs) with polyvinyl alcohol (PVA)-based contact layers for monitoring cardiovascular health. TENGs help conserve mechanical energy and turn it into power.
The Purdue team’s work is published in the journal Advanced Materials.
Among the drugs used for COVID-19 is a particularly promising Cuban compound called “Interferon alfa-2b,” which has been successfully administered to Chinese patients.
In Cuba, where precaution measures against COVID-19 have included the temporary closing of schools and the shutdown of the tourist sector, among others, authorities have called on people to stay at home while Cuban scientists are working hard to develop new biotech products to kill the lethal disease.
With a growing number of cases, the island’s healthcare infrastructure is ready to treat an expected surge of patients with a wide selection of promising drugs. “The package of drugs we are administering is based on the experience of countries hardest hit by the disease. We have considered this with our experts, while our scientists try to add new local drugs to this protocol,” said Cuban Health Minister Jose Angel Portal in a recent TV appearance.
An international team of scientists has collated all known bacterial genomes from the human gut microbiome into a single large database, allowing researchers to explore the links between bacterial genes and proteins, and their effects on human health.
This project was led by EMBL’s European Bioinformatics Institute (EMBL-EBI) and included collaborators from the Wellcome Sanger Institute, the University of Trento, the Gladstone Institutes, and the US Department of Energy Joint Genome Institute. Their work has been published in Nature Biotechnology.
Imagine if this very cheap thing could treat coronavirus 🤔
That would put a wrench in profiteers plans:
Green coffee bean extract is a popular weight loss and health supplement, but does it work, and is it safe?
Green coffee beans, or raw coffee beans, are coffee beans that are not roasted. Green coffee bean extract is a popular weight loss supplement.
Some research also suggests that green coffee bean extract could have health benefits, such as improving blood pressure and cholesterol levels. This belief stems from the antioxidant properties and other pharmacologically active compounds in the unroasted beans.
This article provides a review of green coffee bean extract, a popular weight loss, and health supplement. It looks at the health benefits, research, risks, and dosage.
The Israeli startup CorNeat Vision has received approval to conduct clinical trials of a synthetic cornea that bio-integrates with the human eye.
The Health Ministry-approved trial of the CorNeat KPro will be run at Beilinson Hospital in Petach Tikva on 10 patients suffering from corneal blindness who are either not candidates for or have experienced one or more failed cornea transplants, the company announced last week.
Corporate boards have been debating the need to invest in innovation as a driver of future growth for the better part of a decade.
And while many enterprises have demonstrated an organizational commitment to innovation through standing up dedicated teams, allocating budget, and developing bets for the future, innovation leaders now face a sizable challenge. As the world grapples with the current public health crisis and its long-tail impacts on society and the economy, many CEOs and their boards of directors are looking for reasons not to invest in innovation.
🤔 The WHO Chief is urging African nations to take part in clinical trials for a vaccine, yet is sending a team to China 7 months after the fact, and after China destroyed samples. The same WHO also is complaining about countries handling of the outbreak.
The UN body announced that over 1.4 million infections of COVID-19 are accounted for by health care sector workers, at least 10% of all cases. EU leaders have met to discuss a recovery package. Follow DW for the latest.
The global health crisis is accelerating meta-trends and hurling civilization towards the transhuman future. The disruptors are being disrupted, and the rush is on to digitize and virtualize everything in weeks’ time that otherwise would have taken a few years to play out. Recent surveys show that we have compressed five years in business and consumer digital adoption within a couple of months. https://www.ecstadelic.net/top-stories/the-great-reset-2020-…-look-like
#GreatReset2020
Expert Opinion: We’ll remember this time of tremendous change when we all looked like masked robbers and hijackers, the time of accelerated digital transformation and virtualization, geopolitical polarity, transpired meta-trends such as having more leisur.
The human microbiome—our own personalized bacteria profile—plays a part in our health. The different parts of our body, from our skin to our gut, each have their own microbial profile. A team of researchers decided to explore the bacteria living inside our nose, publishing this week in the journal Cell Reports. Microbiologist Sarah Lebeer, one of the authors of the study, discusses what beneficial bacteria reside in our nose—and how this could be used to create a probiotic for upper respiratory infections.
A team of researchers created a profile of the nose microbiome to help create future probiotics for upper respiratory infections.
Moderna, Inc.’s COVID-19 vaccine candidate mRNA-1273 will advance to a 30,000-participant Phase III trial later this month, following publication of additional positive Phase I data from a study led by the National Institutes of Health (NIH)’s National Institute of Allergy and Infectious Diseases (NIAID).
Moderna said its closely-watched COVID-19 vaccine candidate mRNA-1273 will advance to a 30,000-participant Phase III trial later this month, following publication of additional positive Phase I data from a study led by the NIH’s National Institute of Allergy and Infectious Diseases (NIAID).
The Phase III “COVE” study (NCT04470427) is expected to begin registration at study centers nationwide beginning on July 21 with study initiation set for six days later. The primary endpoint of the randomized, 1:1 placebo-controlled trial will be the prevention of symptomatic COVID-19 disease. Key secondary endpoints include prevention of severe COVID-19 disease as defined by the need for hospitalization, and prevention of infection by SARS-CoV-2, Moderna said.
Moderna disclosed plans for the Phase III trial on Clinicaltrials.gov the same day that researchers from NIAID, Moderna, and their clinical research partners reported that mRNA-1273 induced rapid and strong immune responses against SARS-CoV-2, in an interim analysis of results from their Phase I study (NCT04283461).
